{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T17:48:31Z","timestamp":1759340911972,"version":"3.41.2"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2017,2,1]],"date-time":"2017-02-01T00:00:00Z","timestamp":1485907200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Reports"],"published-print":{"date-parts":[[2017,2]]},"DOI":"10.1016\/j.pharep.2016.09.020","type":"journal-article","created":{"date-parts":[[2016,9,23]],"date-time":"2016-09-23T09:44:11Z","timestamp":1474623851000},"page":"105-111","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Search for new potential anticonvulsants with anxiolytic and antidepressant properties among derivatives of 4,4-diphenylpyrrolidin-2-one"],"prefix":"10.1007","volume":"69","author":[{"given":"Katarzyna","family":"Malawska","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aleksandra","family":"Rak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beata","family":"Gryz\u0142o","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kinga","family":"Sa\u0142at","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ma\u0142gorzata","family":"Micha\u0142owska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"El\u017cbieta","family":"\u017bmudzka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Krzysztof","family":"Lodarski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barbara","family":"Malawska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katarzyna","family":"Kulig","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"10.1016\/j.pharep.2016.09.020_bib0005","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1056\/NEJMra022308","article-title":"Epilepsy","volume":"349","author":"Chang","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pharep.2016.09.020_bib0010","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1111\/j.1528-1167.2008.01579.x","article-title":"The prevalence of epilepsy and pharmacoresistant epilepsy in adults: a population-based study in a Western European country","volume":"49","author":"Picot","year":"2008","journal-title":"Epilepsia"},{"year":"2011","series-title":"The Pharmacological Basis of Therapeutics","author":"McNamara","key":"10.1016\/j.pharep.2016.09.020_bib0015"},{"key":"10.1016\/j.pharep.2016.09.020_bib0020","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1021\/jm00154a022","article-title":"Conformational analysis of clinically active anticonvulsant drugs","volume":"29","author":"Wong","year":"1986","journal-title":"J Med Chem"},{"key":"10.1016\/j.pharep.2016.09.020_bib0025","doi-asserted-by":"crossref","first-page":"69","DOI":"10.2174\/1568026053386944","article-title":"New anticonvulsant agents","volume":"5","author":"Malawska","year":"2004","journal-title":"Curr Top Med Chem"},{"key":"10.1016\/j.pharep.2016.09.020_bib0030","doi-asserted-by":"crossref","first-page":"443","DOI":"10.2174\/0929867023371030","article-title":"Arylpiperazine derivatives acting at 5-HT(1A) receptors","volume":"9","author":"L\u00f3pez-Rodr\u00edguez","year":"2002","journal-title":"Curr Med Chem"},{"key":"10.1016\/j.pharep.2016.09.020_bib0035","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/S1734-1140(12)70772-7","article-title":"Synthesis, anticonvulsant activity and 5-HT1A\/5-HT7 receptors affinity of 1-[(4-arylpiperazin-1-yl)-propyl]-succinimides","volume":"64","author":"Obniska","year":"2012","journal-title":"Pharmacol Rep"},{"key":"10.1016\/j.pharep.2016.09.020_bib0040","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.pharep.2015.06.139","article-title":"The anxiolytic-like activity of a novel N-cycloalkyl-N-benzoylpiperazine derivative","volume":"68","author":"Strub","year":"2016","journal-title":"Pharmacol Rep"},{"key":"10.1016\/j.pharep.2016.09.020_bib0045","doi-asserted-by":"crossref","first-page":"27","DOI":"10.2165\/00023210-200822010-00003","article-title":"Antiepileptic drugs in non-epilepsy disorders: relations between mechanisms of action and clinical efficacy","volume":"22","author":"Johannessen Landmark","year":"2008","journal-title":"CNS Drugs"},{"key":"10.1016\/j.pharep.2016.09.020_bib0050","series-title":"Antiepileptic Drugs","article-title":"General principles: experimental selection, quantification, and evaluation of anticonvulsants","author":"Swinyard","year":"1989"},{"key":"10.1016\/j.pharep.2016.09.020_bib0055","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/BF02229077","article-title":"The early identification of anticonvulsant activity: role of the maximal electroshock and subcutaneous pentylenetetrazol seizure models","volume":"16","author":"White","year":"1995","journal-title":"Ital J Neurol Sci"},{"key":"10.1016\/j.pharep.2016.09.020_bib0060","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/0920-1211(91)90075-Q","article-title":"The role of technical, biological and pharmacological factors in the laboratory evaluation of anticonvulsant drugs. II. Maximal electroshock seizure models","volume":"8","author":"L\u00f6scher","year":"1991","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.pharep.2016.09.020_bib0065","first-page":"97","article-title":"Studies on the mechanism of amphetamine toxicity in aggregated mice","volume":"132","author":"Swinyard","year":"1961","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.pharep.2016.09.020_bib0070","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/S1734-1140(09)70029-5","article-title":"Influence of agmatine on the protective action of numerous antiepileptic drugs against pentetrazole-induced seizures in mice","volume":"61","author":"\u0141uszczki","year":"2009","journal-title":"Pharmacol Rep"},{"key":"10.1016\/j.pharep.2016.09.020_bib0075","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1002\/jps.3030460322","article-title":"A note on a simple apparatus for detecting neurological deficit in rats and mice","volume":"46","author":"Dunham","year":"1957","journal-title":"J Am Pharm Assoc Am Pharm Assoc (Baltim)"},{"key":"10.1016\/j.pharep.2016.09.020_bib0080","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/j.pbb.2005.04.015","article-title":"Anxiolytic-like effect of milnacipran in the four-plate test in mice: mechanism of action","volume":"81","author":"Bourin","year":"2005","journal-title":"Pharmacol Biochem Behav"},{"key":"10.1016\/j.pharep.2016.09.020_bib0085","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.neuropharm.2015.07.037","article-title":"Antidepressant-like effects of ketamine, norketamine and dehydronorketamine in forced swim test: role of activity at NMDA receptor","volume":"99","author":"Sa\u0142at","year":"2015","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.pharep.2016.09.020_bib0090","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/0014-2999(78)90414-4","article-title":"Behavioural despair in rats and mice: strain differences and the effects of imipramine","volume":"51","author":"Porsolt","year":"1978","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.pharep.2016.09.020_bib0095","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.pbb.2013.06.013","article-title":"Evaluation of anxiolytic-like, anticonvulsant, antidepressant-like and antinociceptive properties of new 2-substituted 4-hydroxybutanamides with affinity for GABA transporters in mice","volume":"110","author":"Sa\u0142at","year":"2013","journal-title":"Pharmacol Biochem Behav"},{"key":"10.1016\/j.pharep.2016.09.020_bib0100","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.seizure.2011.01.003","article-title":"Critical review of current animal models of seizures and epilepsy used in the discovery and development of new antiepileptic drugs","volume":"20","author":"L\u00f6scher","year":"2011","journal-title":"Seizure"}],"container-title":["Pharmacological Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1734114016302080?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1734114016302080?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T20:36:42Z","timestamp":1752611802000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1016\/j.pharep.2016.09.020"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,2]]},"references-count":20,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,2]]}},"alternative-id":["S1734114016302080"],"URL":"https:\/\/doi.org\/10.1016\/j.pharep.2016.09.020","relation":{},"ISSN":["1734-1140"],"issn-type":[{"type":"print","value":"1734-1140"}],"subject":[],"published":{"date-parts":[[2017,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Search for new potential anticonvulsants with anxiolytic and antidepressant properties among derivatives of 4,4-diphenylpyrrolidin-2-one","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pharep.2016.09.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Published by Elsevier Sp. z o.o. on behalf of Institute of Pharmacology, Polish Academy of Sciences.","name":"copyright","label":"Copyright"}]}}